[Asia Economy Reporter Lee Gwanju] M2N announced on the 21st that it will collaborate with Dr. Richard Vile, a renowned authority in cancer immunotherapy, to develop anticancer vaccines.
Dr. Vile is a professor of immunology at the Mayo Clinic and a world-renowned expert who has researched cancer vaccines and viruses for 20 years. Based on continuous research, he has published over 300 papers, which are widely utilized in academia. His papers have been cited more than 15,000 times.
Dr. Vile demonstrated the therapeutic effects of combining adoptive cell therapy (ACT) and oncolytic viruses in melanoma patients. He is also researching ways to develop chimeric antigen receptor T cells (CAR-T), which have shown excellent therapeutic effects in leukemia patients, for a broader range of tumor types. Additionally, he is developing treatments that combine commonly used radiation therapies with immunotherapy, such as combining immune-based approaches with external beam therapy and brachytherapy, to enhance therapeutic efficacy.
Dr. Vile will join Greenfire Bio (GFB), M2N's local U.S. subsidiary, and MGFB, a joint venture established by the Mayo Clinic for new drug development. Dr. Vile stated, "I expect that by joining MGFB and succeeding in new drug development, we will be able to offer better treatment options to patients who are unresponsive to existing therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
